Where Might Genentech Investors Redeploy $47 Billion?

Following a spate of high profile clinical setbacks and regulatory delays that sent the sector into a tailspin during the final week of February 2009 (see prior column), investors shrugged off further disappointing clinical news as merger and acquisition activity helped biotechnology

2009: Positive Perspectives for Biotechnology

After a brief bout of euphoria during the early portion of the decade, the biotechnology industry, as measured by the Amex Biotech Index (BTK), was shunned by investors for the better part of the 1990’s. The BTK, which was established with a benchmark value of 200 on October 18, 1991,